baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

AbbVie Inc/ US00287Y1091 /

2024-05-21 10:10:00 PM	Chg. -1.63	Volume	Bid2:00:00 AM	Ask2:00:00 AM	Market Capitalization	Dividend Y.	P/E Ratio
162.93USD	-0.99%	3.65 mill. Turnover: 391.73 mill.	161.19Bid Size: 100	164.93Ask Size: 100	287.71 bill.USD	3.68%	59.68

GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 05-21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

GlobeNewswire 05-21 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...

GlobeNewswire 05-21 Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

GlobeNewswire 05-17 INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerev...

GlobeNewswire 05-16 CytomX Therapeutics Announces New Employment Inducement Grants

GlobeNewswire 05-16 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

GlobeNewswire 05-14 CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough...

GlobeNewswire 05-14 Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

GlobeNewswire 05-14 Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...

GlobeNewswire 05-14 In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit

GlobeNewswire 05-13 Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire 05-11 SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LABP, DOMA, FXNC

GlobeNewswire 05-09 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire 05-09 Royalty Pharma Reports First Quarter 2024 Results

GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

GlobeNewswire 05-09 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...

GlobeNewswire 05-08 CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...

GlobeNewswire 05-08 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Alector Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-08 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...

GlobeNewswire 05-08 Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire 05-08 ArriVent BioPharma Reports First Quarter 2024 Financial Results

GlobeNewswire 05-07 CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...

GlobeNewswire 05-07 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

AbbVie Inc/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.